Tables
TABLE 1 FDA APPROVED DRUGS FOR NEPHROLOGY 2015-2018 9
TABLE 2 CHRONIC KIDNEY DISEASE DRUGS MARKET REVENUE' BY DRUG CLASS' 2018-2025 ($MILLION) 30
TABLE 3 CHRONIC KIDNEY DISEASE DRUGS MARKET REVENUE' BY PRODUCT TYPE' 2018-2025 ($MILLION) 41
TABLE 4 ABBVIE INC.: OFFERINGS 51
TABLE 5 ABBVIE INC.: RECENT DEVELOPMENTS 51
TABLE 6 AMGEN INC.: OFFERINGS 56
TABLE 7 AMGEN INC.: RECENT DEVELOPMENTS 56
TABLE 8 GLAXOSMITHKLINE PLC: OFFERINGS 61
TABLE 9 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 61
TABLE 10 F. HOFFMANN-LA ROCHE LTD.: PRODUCT OFFERINGS 66
TABLE 11 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 66
TABLE 12 ASTRAZENECA PLC: OFFERINGS 71
TABLE 13 ASTRAZENECA PLC: RECENT DEVELOPMENTS 72
TABLE 14 PFIZER INC.: SNAPSHOT 77
TABLE 15 MERCK KGAA: RECENT DEVELOPMENTS 77
TABLE 16 SANOFI: SNAPSHOT 78
TABLE 17 SANOFI: RECENT DEVELOPMENTS 78
TABLE 18 TEVA PHARMACEUTICAL INDUTRIES.: OVERVIEW 79
TABLE 19 TEVA PHARMACEUTICAL INDUTRIES: RECENT DEVELOPMENTS 79
TABLE 20 EDITAS MEDICINE: OVERVIEW 81
TABLE 21 EDITAS MEDICINE.: RECENT DEVELOPMENTS 81
TABLE 22 KERYX BIOPHARMACEUTICALS' INC: SNAPSHOT 81
TABLE 23 KERYX BIOPHARMACEUTICALS' INC: RECENT DEVELOPMENTS 82
TABLE 24 FIBROGEN INC.: OVERVIEW 82
TABLE 25 FIBROGEN INC.: RECENT DEVELOPMENTS 82
?
LIST OF FIGURE
Charts
CHART 1 RESEARCH METHODOLOGY OF GLOBAL CHRONIC KIDNEY DISEASES DRUGS MARKET 12
CHART 2 STAGES OF CHRONIC KIDNEY DISEASE 14
CHART 3 CHRONIC KIDNEY DISEASE DRUGS MARKET REVENUE' 2018-2025 ($MILLION) 15
CHART 4 CHRONIC KIDNEY DISEASE DRUGS MARKET SEGMENTATION 19
CHART 5 PORTERS 5 FORCES ON CHRONIC KIDNEY DISEASE DRUGS MARKET 19
CHART 7 MARKET DYNAMICS - DRIVERS' RESTRAINTS & OPPORTUNITIES 22
CHART 8 WORLD POPULATION AGED 65 YEARS AND ABOVE' 1960-2060 (%) 24
CHART 9 DRO - IMPACT ANALYSIS OF CHRONIC KIDNEY DISEASES DRUGS MARKET 28
CHART 10 KEY STAKEHOLDERS OF CHRONIC KIDNEY DISEASE DRUGS MARKET 29
CHART 11 CHRONIC KIDNEY DISEASES DRUGS MARKET SEGMENT REVENUE BY DRUG CLASS' 2018 VS 2025 ($ MILLION) 30
CHART 12 ANTI-HYPERTENSIVE DRUGS MARKET REVENUE' BY DRUG CLASS 2018-2025 ($MILLION) 32
CHART 13 ANTI-HYPERLIPIDEMIC DRUGS MARKET REVENUE' BY DRUG CLASS 2018-2025 ($MILLION) 33
CHART 14 ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) MARKET REVENUE' BY DRUG CLASS 2018-2025 ($MILLION) 34
CHART 15 CHRONIC KIDNEY DISEASE DRUGS MARKET REVENUE' BY DRUG CLASS 2018-2025 ($MILLION) 36
CHART 16 OTHER CHRONIC KIDNEY DISEASE DRUGS MARKET REVENUE' BY DRUG CLASS 2018-2025 ($MILLION) 37
CHART 17 GLOBAL CHRONIC KIDNEY DISEASE DRUGS MARKET SEGMENT REVENUE' BY END USERS' 2018 (%) 38
CHART 18 CHRONIC KIDNEY DISEASE DRUGS MARKET BY REGIONAL SEGMENTATION' 2018 VS 2025 ($MILLION) 40
CHART 19 CHRONIC KIDNEY DISEASE DRUGS MARKET REVENUE IN NORTH AMERICA' 2018-2025 ($MILLION) 43
CHART 20 CHRONIC KIDNEY DISEASE DRUGS MARKET REVENUE IN EUROPE' 2018-2025 ($MILLION) 44
CHART 21 CHRONIC KIDNEY DISEASE DRUGS MARKET REVENUE IN ASIA PACIFIC' 2018-2025 ($MILLION) 46
CHART 22 CHRONIC KIDNEY DISEASE DRUGS REVENUE IN REST OF THE WORLD' 2018-2025 ($MILLION) 47
CHART 23 ABBVIE INC.: OVERVIEW SNAPSHOT 52
CHART 24 ABBVIE INC.: GEOGRAPHIC PRESENCE 54
CHART 25 ABBVIE INC.: SWOT ANALYSIS 55
CHART 26 AMGEN INC.: OVERVIEW SNAPSHOT 57
CHART 27 AMGEN INC.: GEOGRAPHIC PRESENCE 59
CHART 28 AMGEN INC.: SWOT ANALYSIS 59
CHART 29 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT 61
CHART 30 GLAXOSMITHKLINE PLC: BUSINESS UNITS 62
CHART 31 GLAXOSMITHKLINE PLC: GEOGRAPHIC PRESENCE 63
CHART 32 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 64
CHART 33 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT 66
CHART 34 F. HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS 67
CHART 35 F. HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC REVENUE 68
CHART 36 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 69
CHART 37 ASTRAZENECA PLC: OVERVIEW SNAPSHOT 71
CHART 38 ASTRA ZENECA PLC: BUSINESS UNITS 74
CHART 39 ASTRAZENECA PLC: GEOGRAPHIC PRESENCE 75
CHART 40 ASTRA ZENECA PLC: SWOT ANALYSIS 76
